Glooko, Inc. and Innovation Zed have announced a strategic partnership to develop and deploy digital companion apps for injectable therapies. This collaboration aims to revolutionize the management of injectable medications by providing comprehensive connectivity and data capture solutions for dosing, storage, and injection techniques.
According to Glooko CEO Mike Alvarez, “This partnership will enable us to provide comprehensive support for patients and their healthcare providers, ultimately enhancing the treatment experience and improving outcomes.” The partnership will integrate Innovation Zed’s DOSE platform technology with Glooko’s existing platform, currently used by over 8,200 diabetes clinics worldwide.
Injectable therapies are essential for managing many chronic conditions, but they pose significant challenges. Complex dosing regimens, fear of injections, and variability in injection technique can hinder adherence and compromise safety. This collaboration aims to address these challenges by providing a comprehensive digital solution that supports patients and healthcare providers in optimizing injectable therapies.
The digital companion system, which will seamlessly integrate hardware and software, will offer a range of benefits for patients and healthcare professionals. These include improved adherence through accurate recording and monitoring of dosing schedules, enhanced safety through guidance on proper storage conditions and educational resources on correct injection techniques, increased patient confidence through support and feedback on injection techniques, and streamlined data management through real-time data capture and connectivity.
The partnership also offers industry partners a valuable launchpad into key markets, expanding access and enhancing the accessibility and effectiveness of injectable therapies globally. Additionally, the collaboration presents a unique opportunity for the pharmaceutical industry to gather valuable real-world data in real-time, leading to a deeper understanding of patient behavior.
“We are excited to partner with Innovation Zed to bring this cutting-edge digital companion system to market,” said Alvarez. “This partnership, combined with our ongoing platform development, reflects Glooko’s continued focus on increasing the benefits delivered to patients and clinics.”
Dr. Dean Minnock, CEO of Innovation Zed, also commented on the partnership, stating, “Together, we can offer unparalleled support to patients and healthcare providers, improving the management of injectable therapies worldwide.”
Glooko is a global integrated digital health company that connects patients, providers, biopharma, and medical device partners. Their proven technologies aim to improve health outcomes through personalized, intelligent, and connected care and life sciences platforms. Glooko boasts the largest installed base of patients living with diabetes, with solutions deployed in over 30 countries and used by more than 4.4 million people worldwide.
Innovation Zed is a leading provider of connected health solutions, specializing in developing innovative medical devices to support drug adherence and diabetes management. With a focus on leveraging technology to enhance patient outcomes, Innovation Zed continues to pioneer new methods for personalized condition management and improved drug adherence.
For more information about the partnership or either company, please contact Innovation Zed Media Relations at pr@innovationzed.com or Glooko Media Relations at pr@glooko.com.
